Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 18, 2022 11:50am
188 Views
Post# 34831504

RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus

RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus Virus Safe Handling Content from the - Environmental Health and Safety -  BioSafety Manual - University of Florida

Poxvirus (Vaccinia):

Poxviruses are double-stranded, enveloped DNA viruses belonging to poxvirus family. The viruses provide an excellent tool for recombinant DNA technology due to their large genome size capable of accommodating large inserts, up to 25Kb, and their ability for autonomous replication. 

Following are poxviruses:

Genus Orthopoxvirus e.g. vaccinia, variola, cowpox, monkeypox, and (now eradicated) small pox viruses

Genus Leporipoxvirus e.g. myxoma virus

Genus Molluscipoxvirus e.g. molluscum contagiosum virus (MCV),

Genus Avipoxvirus e.g. canarypox and fowlpox viruses. 

Risk Assessment:

Safety issues arise since these recombinant viruses can replicate in mammalian cells and can cause severe infection in immunocompromised individuals. Laboratory acquired infections have been reported as a result of accidental inoculation.

All projects involving poxviruses are reviewed by the IBC (Institutional Biosafety Committee)
Working with vaccinia is usually recommended at BSL-2 or higher and animal work at ABSL-2 or higher. Final assessment of the biosafety level is decided by the IBC on case-by-case basis.

Monkeypox is a Risk Group 3 (RG3) virus and a select agent. Work with this virus has to be conducted at BSL-3 or above

Researchers working with vaccinia and other poxviruses can potentially get exposed to the virus by ingestion, parenteral inoculation, aerosols, or through broken skin

Researchers who directly handle vaccinia vectors (other than highly attenuated MVA, NYVAC, ALVAC and TROVAC) in culture or work with animals infected with these, are required to receive vaccinia vaccination before they start working with these agents and to get re-vaccinated at least every 10years. Persons working with monkeypox virus must be vaccinated every 3 years.

Immunocompromised individuals must not handle these viruses


Disadvantages of using Vaccinia Viral Vectors:

Non-highly attenuated strains are infectious

Vaccinia vaccination is required for persons working with non-highly attenuated strains.

Immunocompromised individuals must not handle these viruses



https://webfiles.ehs.ufl.edu/BioMan.pdf
<< Previous
Bullboard Posts
Next >>